
The state of Indiana is continuing to grow its reputation in the growing realm of radiopharmaceuticals.
BioCrossroads, the initiative to grow and promote Indiana’s life sciences sector, said Monday that the state has secured the designation of Radiopharmaceutical Capital of the World from the U.S. Patent and Trademark Office.
Radiopharmaceuticals are drugs that contain radioisotopes and are used to treat various medical conditions, including different types of cancer and hyperthyroidism. According to Purdue University, the nuclear medicine market is a $6 billion industry in the U.S.
BioCrossroads said Indiana has established itself as a major player in radiopharmaceuticals with several companies setting up production facilities in different parts of the state.
Indianapolis-based SpectronRx opened its headquarters in 2019 and has grown from a staff of six to 175 in Indianapolis as of December 2024. The company also has a facility near the Grissom Air Reserve Base in Bunker Hill used to produce medical isotopes used in radiopharmaceuticals.
Switzerland-based drugmaker Novartis opened a $100 million facility near Indianapolis International Airport in April 2024, and just one month later, announced plans to invest an additional $125 million to expand the facility.
The facility is used to make Pluvicto, a drug originally developed by Dr. Philip Low at Purdue University, treats patients with advanced-stage prostate cancer.
RayzeBio, recently acquired by Bristol Myers Squibb in a $4.1 billion deal, recently opened its targeted radiopharmaceutical therapy facility in Indiana. The state is also home to a growing number of innovators including AZIsotopes, Oranomed, Curium, and Telix Pharmaceuticals.
“Indiana’s designation as the Radiopharmaceutical Capital of the World is a testament to the strength of our life sciences ecosystem, the innovation of our researchers, and the collaborative spirit that drives us forward,” BioCrossroads CEO Vince Wong said in a news release. “We’ll leverage this fitting title to further elevate Indiana as a center of excellence in this exciting, dynamic area of medicine that is helping transform the standard of care to the benefit of patients throughout the world.”
The designation follows the announcement earlier this month that Purdue University and SpectronRx are partnering on a graduate degree program focused directly on radiopharmaceutical manufacturing.
We’ll have more on Indiana’s impact on the radiopharmaceutical industry on this weekend’s edition of Inside INdiana Business with Gerry Dick.
